reference/5932413

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/5932413

Outgoing Links

Predicate	Object
contentType	Journal Article\|Review
endingPage	1853
issn	1042-8194 1029-2403
issueIdentifier	8
pageRange	1849-1853
publicationName	Leukemia & Lymphoma
startingPage	1849
bibliographicCitation	te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC). Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Aug;54(8):1849–53. doi: 10.3109/10428194.2013.796058. PMID: 23614766.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_13171e0c2a2ef80c3ff18446a78fd110 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d78451a78760cb91d7d80b55dcc044bf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dd45ddc440b556663a5cfc5a8c7a68ef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8637163c90f04125ada32f0741ddfa09 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_238ea04eee877ec18db6c2cd461c8de1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc1da7b53f142df705dca43bd8839e4e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_45de9de842912fb1d7a1516d48b196dd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd47b8dba9816ebc88f7e7063aca0a38 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e19ab3dd0d3b994c70ef89cfcdc51e06 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7430-1143 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5089-344X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d5e96ff7b5e3364baa087513b199f5e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_46e580d71b0d29b78e5f28ec17372a15 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7136-2680 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3780-274X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d0a361fb8db694cda5fc51c1f5b4dfdc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1f07f07ad4a34c1cfedf8cf5b7b51265 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd29416148f4af38311ba107899e7c21 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_881417f3fe5d49913d97b50252f7b506 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_261b33c5f5c6b21ee48ebb9270110f45
date	2013-06-24^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.3109/10428194.2013.796058 https://pubmed.ncbi.nlm.nih.gov/23614766
isPartOf	https://portal.issn.org/resource/ISSN/1029-2403 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2306 https://portal.issn.org/resource/ISSN/1042-8194
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Overview of available p53 function tests in relation toTP53andATMgene alterations and chemoresistance in chronic lymphocytic leukemia
discusses	http://id.nlm.nih.gov/mesh/M0248389 http://id.nlm.nih.gov/mesh/M0024670
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D019008Q000235 http://id.nlm.nih.gov/mesh/D015451Q000235 http://id.nlm.nih.gov/mesh/D064007Q000235 http://id.nlm.nih.gov/mesh/D015451Q000378 http://id.nlm.nih.gov/mesh/D016159Q000235 http://id.nlm.nih.gov/mesh/D016159Q000378
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D016133Q000379 http://id.nlm.nih.gov/mesh/D005434Q000379 http://id.nlm.nih.gov/mesh/D015398 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D015451Q000175
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9720 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_bf99a94c673fe4e93461af6be7e99f9e http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c5341e883d09ced169abfac23dc13abc http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_75be19437755fc2af3f5756d6bb1d737 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_52a517e173e6fa70285ded085be0d86f http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_24fcc8ae2c4a3fc4fe2b5ecda59a20f4 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f1b2452da84551fc91db93425b6a20d9 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_582d5f2f504253c89e3a8210d6134600

Showing number of triples: 1 to 60 of 60.